The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-5996
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal ; volume:14 ; number:1 ; day:14 ; month:2 ; year:2022 ; pages:1-14 ; date:12.2022
Diabetology & metabolic syndrome ; 14, Heft 1 (14.2.2022), 1-14, 12.2022
- Creator
-
Malkin, Samuel J. P.
Carvalho, Davide
Costa, Catarina
Conde, Vasco
Hunt, Barnaby
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13098-022-00801-4
- URN
-
urn:nbn:de:101:1-2022051921064677048769
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Malkin, Samuel J. P.
- Carvalho, Davide
- Costa, Catarina
- Conde, Vasco
- Hunt, Barnaby
- SpringerLink (Online service)
Other Objects (12)
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States
Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
Oral Semaglutide: Dosage in Special Situations
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Semaglutide
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States
Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
Oral Semaglutide: Dosage in Special Situations
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Semaglutide
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States
Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
Oral Semaglutide: Dosage in Special Situations
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China